phrykt

Olema Oncology, Inc. (OLMA): who owns it and who trades it

As of Nov 16, 2026, OLMA insiders reported 25 open-market sales worth $24.7M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Ian T Clark (Director), with $7.9M.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

In the last 12 months, OLMA insiders reported $0 of open-market purchases and $24.7M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$24.7M
25 trades, 6 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Jul 24, 2026
Filed Jul 27, 2026

Purchases and sales by month

$17M$17MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Jul 24, 2026Cyrus HarmonDirectorSale12,500$11.71$146KForm 4
Jul 23, 2026Cyrus HarmonDirectorSale12,500$11.58$145KForm 4
Mar 4, 2026Shawnte MitchellCHIEF LEGAL OFFICERSale233$24.69$5.8KForm 4
Mar 4, 2026Shawnte MitchellCHIEF LEGAL OFFICERSale24,767$24.25$601KForm 4
Mar 3, 2026Shawnte MitchellCHIEF LEGAL OFFICERSale15,000$23.01$345KForm 4
Jan 20, 2026Cyrus HarmonDirectorSale10,000$26.88$269KForm 4
Jan 15, 2026Shane William Charles KovacsCH. OPERATING & FINANCIASale100,000$28.73$2.9MForm 4
Jan 14, 2026Cyrus HarmonDirectorSale3,489$29.12$102KForm 4
Jan 14, 2026David C. MylesCH. DISCOV. & NON-CLIN DSale14,997$28.60$429KForm 4
Jan 14, 2026David C. MylesCH. DISCOV. & NON-CLIN DSale35,003$28.99$1MForm 4
Jan 13, 2026Shane William Charles KovacsCH. OPERATING & FINANCIASale3,822$28.01$107KForm 4
Jan 13, 2026David C. MylesCH. DISCOV. & NON-CLIN DSale49,800$27.60$1.4MForm 4
Jan 13, 2026David C. MylesCH. DISCOV. & NON-CLIN DSale200$28.49$5.7KForm 4
Jan 12, 2026David C. MylesCH. DISCOV. & NON-CLIN DSale10,000$28.34$283KForm 4
Dec 23, 2025Naseem ZojwallaChief Medical OfficerSale99,509$27.66$2.8MForm 4
Dec 22, 2025Cyrus HarmonDirectorSale2,881$28.53$82.2KForm 4
Dec 22, 2025Naseem ZojwallaChief Medical OfficerSale100,000$28.04$2.8MForm 4
Dec 19, 2025Ian T ClarkDirectorSale29,904$28.83$862KForm 4
Dec 19, 2025Ian T ClarkDirectorSale193,056$29.71$5.7MForm 4
Dec 19, 2025Ian T ClarkDirectorSale41,840$30.48$1.3MForm 4
Dec 19, 2025David C. MylesCH. DISCOV. & NON-CLIN DSale6,046$31.39$190KForm 4
Dec 19, 2025David C. MylesCH. DISCOV. & NON-CLIN DSale43,729$30.40$1.3MForm 4
Dec 19, 2025David C. MylesCH. DISCOV. & NON-CLIN DSale1,225$28.08$34.4KForm 4
Dec 19, 2025Naseem ZojwallaChief Medical OfficerSale57,079$28.03$1.6MForm 4
Dec 19, 2025Naseem ZojwallaChief Medical OfficerSale12,921$28.93$374KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Ian T ClarkDirector–$7.9MDec 19, 2025
Naseem ZojwallaChief Medical Officer–$7.5MDec 23, 2025
David C. MylesCH. DISCOV. & NON-CLIN DEV OFF–$4.7MJan 14, 2026
Shane William Charles KovacsCH. OPERATING & FINANCIAL OFF.–$3MJan 15, 2026
Shawnte MitchellCHIEF LEGAL OFFICER–$952KMar 4, 2026
Cyrus HarmonDirector–$744KJul 24, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

OLMA short interest

High short interest. 19.6% of OLMA shares are sold short: about 1 share in 5. Over the last 12 reports the number of shares short went up 48%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 17.12M OLMA shares were sold short, 19.6% of the shares outstanding, up 9.2% from the report before. At the average daily volume of 1.44M shares, buying them all back would take about 11.9 trading days (days to cover).

Shares short, % of all shares

19.6%May 15Oct 3020.5%

Days to cover

11.9May 15Oct 3020.5

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202617.12M19.57%+9%1.44M11.9
Oct 15, 202615.68M17.92%+7%1.17M13.4
Sep 30, 202614.70M16.80%-9%1.44M10.2
Sep 15, 202616.07M18.36%+3%1.01M15.9
Aug 31, 202615.66M17.90%-1%845,05218.5
Aug 14, 202615.81M18.07%-1%1.11M14.2
Jul 31, 202615.96M18.32%+6%876,85418.2
Jul 15, 202615.10M17.33%+8%1.34M11.3
Jun 30, 202614.03M16.10%+9%2.47M5.7
Jun 15, 202612.84M14.74%+8%1.63M7.9
May 29, 202611.93M13.69%+3%1.13M10.5
May 15, 202611.59M13.30%-11%1.13M10.2

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Olema Oncology company events

Olema Oncology filed 15 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Nov 10, 2026.

  1. Nov 10, 2026ResultsReleased financial results. Filing
  2. Oct 15, 2026LeadershipDr. Gorjan Hrustanovic notified Olema Pharmaceuticals, Inc. of his decision to resign from the Company’s Board of Directors, effective October 14, 2026. Filing
  3. Aug 13, 2026LeadershipOlema Pharmaceuticals, Inc. announced the appointment of Jason O’Byrne as the Company’s Chief Financial Officer, principal financial officer and principal accounting officer, which was approved by the Board of Directors of the Company on July 28, 2026 and effective as of August 11, 2026. Filing
  4. Aug 10, 2026ResultsReleased financial results. Filing
  5. Jun 23, 2026VoteReported shareholder vote results. Filing
  6. May 26, 2026AnnouncementAs described above, on May 26, 2026, the Company announced that it had entered into the Agreement with Bayer. Filing
  7. May 21, 2026AnnouncementAs described above, on May 21, 2026, the Company announced preliminary clinical data from its Phase 1 study of OP-3136. Filing
  8. May 12, 2026ResultsReleased financial results. Filing
  9. May 1, 2026AgreementOlema Pharmaceuticals, Inc. entered into a lease agreement with KR Oyster Point II, LLC, a Delaware limited liability company, pursuant to which the Company will lease an aggregate of approximately 38,176 square feet, consisting of 25,048 square feet of space located on the fourth floor and 13,128… Filing
  10. Apr 29, 2026LeadershipUpon recommendation from the Nominating and Corporate Governance Committee of the Board of Directors of Olema Pharmaceuticals, Inc., the Board appointed Dr. Prakash Raman to the Board as a Class II director, effective April 28, 2026. Filing
  11. Mar 16, 2026ResultsReleased financial results. Filing
  12. Jan 30, 2026LeadershipOlema Pharmaceuticals, Inc. announced that Shane Kovacs, the Company’s Chief Operating and Financial Officer, is departing the Company effective January 30, 2026 to pursue new opportunities. Filing
  13. Jan 12, 2026ResultsReleased financial results. Filing
  14. Nov 19, 2025AnnouncementOlema Pharmaceuticals, Inc. entered into an underwriting agreement with TD Securities (USA) LLC, as representative of the several underwriters named therein, relating to the issuance and sale in a public offering of 10,000,000 shares of the Company’s common stock, par value $0.0001 per share, at a… Filing
  15. Nov 18, 2025AnnouncementThe Company terminated the prospectus related to the sale of its common stock, $0.0001 par value per share in an “at-the-market” offering pursuant to the terms of the Sales Agreement, dated January 6, 2025, by and between the Company and TD Securities (USA) LLC. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Olema Oncology financials

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named OLMA in the last 120 days.

FiledHolderFormStake
Nov 16, 2026JANUS HENDERSON GROUP Ltd.13G/A7.2%
Nov 16, 2026JANUS HENDERSON GROUP Ltd.13G/A7.2%
Oct 16, 2026BIOTECHNOLOGY VALUE FUND L P13D/A6.6%
Oct 16, 2026BIOTECHNOLOGY VALUE FUND L P13D/A6.6%

Questions about Olema Oncology, Inc. (OLMA) stock

Are OLMA insiders buying or selling?

In the last 12 months, OLMA insiders reported no open-market purchases and 25 sales worth $24.7M. The latest trade was on Jul 24, 2026. See every trade.

What is the short interest in OLMA?

As of Oct 30, 2026, 17.12M OLMA shares were sold short, 19.6% of the shares outstanding, up 9.2% from the report before. At the average daily volume of 1.44M shares, buying them all back would take about 11.9 trading days (days to cover). See the history.

Executive pay

Olema Oncology's chief executive was paid a total of $3.2M for the year ended Dec 31, 2025, down 61% from $8.1M the year before. In the last 12 months, Olema Oncology's executives and directors bought no stock on the open market and sold $24.7M.

Chief executive, total pay$3.2MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$25.2MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$2MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.